Literature DB >> 1973409

Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis.

B Carlsson1, J Wallin, R Pirskanen, G Matell, C I Smith.   

Abstract

We have investigated the HLA-DRB and -DQB gene polymorphism in 131 myasthenia gravis (MG) patients. The HLA genotypes in these patients were assigned by means of restriction fragment length polymorphism (RFLP)-defined DR-DQ haplotypes, correlating to serologic HLA class II typing. Using this technique we could, among randomly selected non-thymomatous (NT)-MG patients, confirm the strong association to DR3, and 70% of the patients were found to carry a specific DR3-positive DR-DQ haplotype, T-3.1. Furthermore, an analysis of T-3.1- NT-MG patients revealed that 59% were T-4.1+ (DR4, DQw8). Thymic hyperplasia was found in approximately 85% of the T-3.1+, as well as of the T-4.1+/3.1- patients. As previously observed, we found a clear dominance of females among the T-3.1+ NT-MG patients. However, among T-4.1+/3.1- patients, males were as common as females. Furthermore, the T-4.1+ patients were significantly older at the onset of disease than those who were T-3.1+. In female MG patients, the DRw15-Dw2-positive haplotype T-2.1 was strongly correlated with the presence of thymoma (T-MG). These data indicate that the HLA associations in early vs late onset of NT-MG are different, and that female patients with and without thymoma differ from each other with regard to HLA markers. Thus, at least three different HLA DR-DQ associations are found in subgroups of idiopathic MG.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973409     DOI: 10.1007/bf02115001

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  33 in total

1.  Drainage of thoracic duct lymph in twelve patients with myasthenia gravis.

Authors:  K Bergström; C Franksson; G Matell; B Y Nilsson; A Persson; G von Reis; R Stensman
Journal:  Eur Neurol       Date:  1975       Impact factor: 1.710

Review 2.  DNA polymorphism of HLA class I and class II regions.

Authors:  D Cohen; P Paul; I Le Gall; A Marcadet; M P Font; O Cohen-Haguenauer; B Sayagh; H Cann; J M Lalouel; J Dausset
Journal:  Immunol Rev       Date:  1985-07       Impact factor: 12.988

3.  Individuals with HLA-DR blank alleles display well-known DR-DQ RFLPs.

Authors:  J Wallin; B Carlsson; O Olerup; E Möller
Journal:  Tissue Antigens       Date:  1989-07

4.  A systematic study of HLA class II-beta DNA restriction fragments in insulin-dependent diabetes mellitus.

Authors:  O Cohen-Haguenauer; E Robbins; C Massart; M Busson; I Deschamps; J Hors; J M Lalouel; J Dausset; D Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis.

Authors:  J R Oksenberg; M Sherritt; A B Begovich; H A Erlich; C C Bernard; L L Cavalli-Sforza; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

6.  Histocompatibility (HL-A) antigens associated with myasthenia gravis. A preliminary report.

Authors:  R Pirskanen; A Tiilikainen; E Hokkanen
Journal:  Ann Clin Res       Date:  1972-10

Review 7.  DNA-RFLP analysis and genotyping of HLA-DR and DQ antigens.

Authors:  J Bidwell
Journal:  Immunol Today       Date:  1988-01

8.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

9.  A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis.

Authors:  G C Harcourt; N Sommer; J Rothbard; H N Willcox; J Newsom-Davis
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

10.  HLA-DQ beta-chain polymorphism linked to myasthenia gravis.

Authors:  J Bell; L Rassenti; S Smoot; K Smith; C Newby; R Hohlfeld; K Toyka; H McDevitt; L Steinman
Journal:  Lancet       Date:  1986-05-10       Impact factor: 79.321

View more
  4 in total

1.  A genome-wide association study of myasthenia gravis.

Authors:  Alan E Renton; Hannah A Pliner; Carlo Provenzano; Amelia Evoli; Roberta Ricciardi; Michael A Nalls; Giuseppe Marangi; Yevgeniya Abramzon; Sampath Arepalli; Sean Chong; Dena G Hernandez; Janel O Johnson; Emanuela Bartoccioni; Flavia Scuderi; Michelangelo Maestri; J Raphael Gibbs; Edoardo Errichiello; Adriano Chiò; Gabriella Restagno; Mario Sabatelli; Mark Macek; Sonja W Scholz; Andrea Corse; Vinay Chaudhry; Michael Benatar; Richard J Barohn; April McVey; Mamatha Pasnoor; Mazen M Dimachkie; Julie Rowin; John Kissel; Miriam Freimer; Henry J Kaminski; Donald B Sanders; Bernadette Lipscomb; Janice M Massey; Manisha Chopra; James F Howard; Wilma J Koopman; Michael W Nicolle; Robert M Pascuzzi; Alan Pestronk; Charlie Wulf; Julaine Florence; Derrick Blackmore; Aimee Soloway; Zaeem Siddiqi; Srikanth Muppidi; Gil Wolfe; David Richman; Michelle M Mezei; Theresa Jiwa; Joel Oger; Daniel B Drachman; Bryan J Traynor
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

Review 2.  What can the HLA transgenic mouse tell us about autoimmune diabetes?

Authors:  F S Wong; L Wen
Journal:  Diabetologia       Date:  2004-09-02       Impact factor: 10.122

3.  An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes.

Authors:  M A Degli-Esposti; A Andreas; F T Christiansen; B Schalke; E Albert; R L Dawkins
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

4.  Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.

Authors:  Angelina H Maniaol; Ahmed Elsais; Åslaug R Lorentzen; Jone F Owe; Marte K Viken; Hanne Sæther; Siri T Flåm; Geir Bråthen; Margitta T Kampman; Rune Midgard; Marte Christensen; Anna Rognerud; Emilia Kerty; Nils Erik Gilhus; Chantal M E Tallaksen; Benedicte A Lie; Hanne F Harbo
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.